Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Depreciation & Amortization (CF) (2016 - 2023)

Historic Depreciation & Amortization (CF) for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $123000.0.

  • Aptevo Therapeutics' Depreciation & Amortization (CF) fell 4459.46% to $123000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $612000.0, marking a year-over-year decrease of 3855.42%. This contributed to the annual value of $567000.0 for FY2023, which is 3706.99% down from last year.
  • As of Q3 2023, Aptevo Therapeutics' Depreciation & Amortization (CF) stood at $123000.0, which was down 4459.46% from $150000.0 recorded in Q2 2023.
  • Over the past 5 years, Aptevo Therapeutics' Depreciation & Amortization (CF) peaked at $583000.0 during Q1 2019, and registered a low of $123000.0 during Q3 2023.
  • For the 5-year period, Aptevo Therapeutics' Depreciation & Amortization (CF) averaged around $323000.0, with its median value being $295000.0 (2021).
  • The largest annual percentage gain for Aptevo Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 68.14% (2019), contrasted with its biggest fall of 6939.46% (2019).
  • Over the past 5 years, Aptevo Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $533000.0 in 2019, then tumbled by 35.83% to $342000.0 in 2020, then decreased by 25.15% to $256000.0 in 2021, then plummeted by 37.11% to $161000.0 in 2022, then decreased by 23.6% to $123000.0 in 2023.
  • Its Depreciation & Amortization (CF) was $123000.0 in Q3 2023, compared to $150000.0 in Q2 2023 and $178000.0 in Q1 2023.